Hereditary Angioedema Treatment Market

Posted by ahila on April 24th, 2018

Hereditary angioedema is an inherited condition characterized by re-occurant severe swelling. It affects arms, face, legs, airway and intestinal tract commonly. Having low level of C1 inhibitor, which is a protein that leads to excess activation of bradykinin which is a primary reason for angioedema. There are three types of hereditary angioedema Type-I, Type-II and Type-III. Type-I is characterised by low levels of C-1 inhibitor whereas Type -II characterised by normal or high levels of C-1 inhibitor. Type-III pathology is unknown. Usually symptoms will begin from puberty but may be seen even earlier. Minor trauma or stress may trigger the attack, however, swelling often occurs without a known trigger. Angioedema occurs in intestinal tract may lead to severe abdominal pain, nausea, and vomiting. Swelling in airway can obstruct passage of air and may lead to life threatening condition.

Global hereditary angioedema treatment market is mainly driven by increase in R&D to treat angioedema. In addition, increase in prevalence and promising pipeline are expected to boost the hereditary angioedema treatment market. Furthermore, change in lifestyle, improved reimbursement infrastructure, and healthcare spending are expected to bolster the hereditary angioedema treatment market. However, high cost of prophylaxis and misdiagnosis of the condition are expected to hinder the hereditary angioedema treatment market during the forecast period.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-hereditary-angioedema-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

Hereditary angioedema treatment market has been segmented based on type, drug class, and distribution channel

Base on type, hereditary angioedema treatment market is segmented into